Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Varsha Gandhi, PhD, on Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

May

Today In Oncology

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Varsha Gandhi, PhD, on Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

AYA Leukemia Survivors Have Higher Mortality Rates Than the General Population

3 vs 6 Months of Adjuvant Oxaliplatin- and Fluoropyrimidine-Based Therapy for Stage III Colon Cancer

Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer

Prevalence of Plasma Cell and Lymphoproliferative Disorders in Relatives of Probands With Light Chain Amyloidosis

Mortality and Perioperative Outcomes With Open vs Robot-Assisted Radical Cystectomy for Bladder Cancer